Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
Melanoma | D008545 | — | — | 1 | — | — | — | — | 1 |
Drug common name | BELVARAFENIB |
INN | belvarafenib |
Description | Belvarafenib (developed by Hanmi Pharmaceuticals and Genentech) is a small molecule RAF dimer (type II) inhibitor which shows anti-tumor clinical activity in cancer patients with BRAFV600E- and NRAS- mutations.
|
Classification | Small molecule |
Drug class | rapidly accelerated fibrosarcoma (RAF) kinase inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12 |
PDB | — |
CAS-ID | 1446113-23-0 |
RxCUI | — |
ChEMBL ID | CHEMBL3977543 |
ChEBI ID | — |
PubChem CID | 89655386 |
DrugBank | — |
UNII ID | 31M3WLJ3KG (ChemIDplus, GSRS) |